Haleon (HLN) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $43.77B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | GB | CEO | Brian James McNamara |
| IPO Date | 2022-07-25 | CAGR | 4.09% |
| Employees | 24,535 | Website | www.haleon.com |
| Div. Yield | 0.7% | Payout Ratio | 40% |
| Buy Back Yield | 0.55% | Total Yield | 1.25% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $43.18B | P/E | 24.87 | Forward P/E | 16.35 | PEG | 0.22 |
| P/S | 10.73 | P/B | 5.5 | P/CF | 87.73 | P/FCF | 94.65 |
| Sales | $25.89B | Sales 1Y | 13.67% | Sales 3Y | — | Sales 5Y | — |
| EPS | $0.4 | EPS 1Y | 40.55% | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 0.65% | EPS QoQ | 5.56% | Sales QoQ Avg | 37.34% | EPS QoQ Avg | 27.22% |
| Gross Margin | 61.45% | Operating Margin | 18.85% | Profit Margin | 12.59% | ROCE | 5.61% |
| ROA | 3% | ROE | 6% | Altman Z Score | 3.44 | Piotroski Score | 8 |
| Current Ratio | 0.92 | Quick Ratio | 0.71 | Cash Ratio | 0.27 | Op. CF Ratio | 0.3 |
| Debt/Equity | 0.52 | Debt/Assets | 0.26 | Lt Debt/Equity | 0.47 | Lt Debt/Cap. | 0.32 |
| Intrst Cov. | 12.83 | Inventory Turnover | 3.1 | Asset Turnover | 0.25 | Receivables Turnover | 3.88 |
| Enterprise Value | $43.18B | P/E Ratio | 24.87 |
| Forward P/E | 16.35 | PEG Ratio | 0.22 |
| P/S Ratio | 10.73 | P/B Ratio | 5.5 |
| P/CF Ratio | 87.73 | P/FCF Ratio | 94.65 |
| EPS | $0.4 | EPS Growth 1Y | 40.55% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 13.67% | Gross Margin | 0.61% |
| Operating Margin | 0.19% | Profit Margin | 0.13% |
| ROE | 0.06% | ROA | 0.03% |
| ROCE | 0.06% | Current Ratio | 0.92 |
| Quick Ratio | 0.71 | Cash Ratio | 0.27 |
| Debt/Equity | 0.52 | Interest Coverage | 12.83 |
| Altman Z Score | 3.44 | Piotroski Score | 8 |
Haleon (HLN) valuation & financials
Haleon (HLN) has a market capitalization of $43.77B and trades at a price-to-earnings ratio of 24.9. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Haleon's revenue grew +13.7% over the last year.
Haleon's next earnings report is scheduled for July 30, 2026 before market open; analysts estimate EPS of $0.27.
Haleon (HLN) — frequently asked questions
When does Haleon (HLN) report earnings next?
Haleon is expected to report earnings on July 30, 2026 before market open. Analysts estimate EPS of $0.27.
What is Haleon's market cap?
Haleon (HLN) has a market capitalization of $43.77B.
What is HLN's P/E ratio?
Haleon trades at a price-to-earnings ratio of 24.9, with trailing twelve-month EPS of $0.40.
How fast is Haleon growing?
Haleon's revenue grew +13.7% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)